For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Iovance Biotherapeutics, Inc.

USPTO Granted Patents = 92

EPO Patents = 12

Trademarks = 21

Forward Citations = 714

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Michael T Lotze (67 out of 73 patents)

Seth Wardell (47 out of 51 patents)

James Bender (45 out of 63 patents)

4. Ian Frank (21 out of 21 patents)

5. Cecile Chartier-Courtaud (7 out of 11 patents)

6. Krit Ritthipichai (7 out of 7 patents)

7. Anne Brooks (5 out of 5 patents)

8. Steve Macrides (5 out of 5 patents)

9. Kristin Lanzi (5 out of 5 patents)

10. Michelle R Simpson-Abelson (4 out of 4 patents)

11. Christopher Mosychuk (4 out of 4 patents)

12. Brian Rabinovich (3 out of 3 patents)

13. Maria Fardis (3 out of 26 patents)

14. Natalia Martin-Orozco (2 out of 2 patents)

15. Laszlo Radvanyi (2 out of 2 patents)

Core Competencies:

Tumor Infiltrating Lymphocytes

Immunotherapy

TIL Expansion

AKT Pathways Inhibitors

Gene Editing

Cytokine Combinations

PD-L1 Binding Proteins

Patient-Specific Immunotherapy

Cryopreserved Lymphocytes

Antigen-Specific T-Cells

Artificial Antigen Presenting Cells

Double-Refractory Melanoma

92 patents: Sort by Forward Citations

1. 12453697 - Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy (2025-10-28),

2. 12343380 - Expansion of TILs utilizing AKT pathways inhibitors (2025-07-01),

3. 12280140 - Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy (2025-04-21),

4. 12233075 - Remnant tumor infiltrating lymphocytes and methods of preparing and using the same (2025-02-25),

5. 12230379 - Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy (2025-02-18),

6. 12230378 - Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy (2025-02-18),

7. 12226434 - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy (2025-02-18),

8. 12194061 - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy (2025-01-14),

9. 12188048 - Restimulation of cryopreserved tumor infiltrating lymphocytes (2025-01-07),

10. 12170134 - Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy (2024-12-17),

11. 12159700 - Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy (2024-12-03),

12. 12121541 - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-10-22),

13. 12104172 - Processes for generating TIL products enriched for tumor antigen-specific t-cells (2024-10-01),

14. 12031157 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-07-09),

15. 12024718 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-07-02),

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of transformative cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. Their proprietary TIL platform aims to improve the outcome for cancer patients by leveraging the power of the body's immune system to target and destroy tumors. With a focus on solid tumors, Iovance Biotherapeutics is dedicated to advancing innovative cell therapies that have the potential to provide long-lasting responses and improve overall survival rates.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

92 Patents

#3 in San Carlos, CA

#933 in California

#3,915 in US

#8,094 in the World

San Carlos, CA, United States of America

Iovance Biotherapeutics, Inc.

Forward Citations = 714

26 inventors:

Michael T Lotze (67 out of 73 patents)

Seth Wardell (47 out of 51 patents)

James Bender (45 out of 63 patents)

4. Ian Frank (21 out of 21 patents)

5. Cecile Chartier-Courtaud (7 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…